Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

info@bullrun.co.in

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

  1. Home
  2. /
  3. Sectors
  4. /
  5. Pharmaceuticals
  6. /
  7. Zydus Lifesciences Ltd
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsBalance SheetProfit & LossCash Flow
HomeStocksPharmaceuticalsZydus Lifesciences Ltd

Zydus Lifesciences Ltd Stock Price Today (NSE: ZYDUSLIFE)

Zydus Lifesciences Ltd

📊 Nifty Next 50
ZYDUSLIFEPharmaceuticals
₹871.20+₹0.00 (+0.00%)↑
As on 30 Mar 2026, 12:03 pm ISTMarket Closed

Fundamental Score

...

Zydus Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Zydus Lifesciences Ltd share price today is ₹871.20, up +0.00% on NSE/BSE as of 30 March 2026. Zydus Lifesciences Ltd (ZYDUSLIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹94.25K (Cr). The 52-week high for ZYDUSLIFE share price is ₹1059.05 and the 52-week low is ₹795.00. At a P/E ratio of 18.74x, ZYDUSLIFE is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.21% and a debt-to-equity ratio of 0.38.

Zydus Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.00%

Returns & Performance

Excellent

ROE

21.21%
Excellent

ROCE

24.31%
Excellent

OPM (5Y)

25.73%
Good

Div Yield

1.17%

Zydus Lifesciences Ltd Valuation Check

Excellent

P/E Ratio

18.74x
Poor

Industry P/E

31.77x
Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Market Cap

94.25K (Cr)

Growth Engine

Excellent

Profit Growth (Q)

40.92%
Good

Sales Growth (Q)

16.92%
Average

Sales Growth (5Y)

10.27%
Excellent

EPS Growth (5Y)

26.36%
Excellent

Profit Growth (5Y)

25.92%

Balance Sheet Health

Good

Debt to Equity

0.38x
Excellent

Int. Coverage

23.80x

Free Cash Flow (5Y)

12.62K (Cr)

Shareholding

Excellent

Promoter

74.99%
Average

FII

7.34%
Good

DII

10.86%
Excellent

Pledged

0.00%

Institutional Deep-Dive

Bull Run Research Hub

Zydus Lifesciences Share Price: A Financial Stability Analysis

One key industry insight in the pharmaceutical sector is the increasing emphasis on research and development (R&D) for novel drug discoveries and generic formulations, directly impacting long-term growth. This analysis explores the financial stability of Zydus Lifesciences, focusing on factors influencing the Zydus Lifesciences share price. The current price stands at ₹888.150024, with a Price-to-Earnings (PE) ratio of 18.74 and a Return on Capital Employed (ROCE) of 24.31%. This report is a segment of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra.

A crucial aspect of evaluating Zydus Lifesciences' financial health is its profitability. The PE ratio of 18.74 suggests a market expectation of future earnings growth, though a deeper dive into earnings quality is essential. Comparing Zydus Lifesciences Ltd with peers like Mankind Pharma Ltd, the management's strategic decisions regarding R&D investment and operational efficiency are particularly relevant. While Mankind Pharma Ltd may exhibit strengths in different areas, a comparative assessment of management quality necessitates analyzing capital allocation decisions and responses to regulatory changes.

The ROCE of 24.31% is a significant indicator of Zydus Lifesciences' capital efficiency. This robust ROCE contributes directly to strengthening the company's economic moat. A higher ROCE means the company generates more profit from its invested capital, allowing it to reinvest in growth opportunities, such as new product development or market expansion, more effectively than competitors with lower ROCEs. This strengthens its competitive advantage and sustains profitability.

Considering the provided data, further in-depth analysis is warranted. This includes assessing the company's debt levels, cash flow generation, and the sustainability of its ROCE. Competitor analysis within the sector, including Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, would provide a more nuanced understanding of Zydus Lifesciences' relative financial position and potential risks. The analysis presented observes current data points; a conclusion on investment is not provided.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Zydus Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ZYDUSLIFE across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (21.21%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (24.31%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (25.73%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 18.74 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (40.92%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (16.92%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (26.36% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (25.92% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (23.80x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹12623.10 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (74.99%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

0 factors identified

No significant concerns identified in current analysis.

Zydus Lifesciences Ltd Financial Statements

Comprehensive financial data for Zydus Lifesciences Ltd including income statement, balance sheet and cash flow

About ZYDUSLIFE (Zydus Lifesciences Ltd)

Zydus Lifesciences Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing global health. The company meticulously researches..., develops, manufactures, and distributes a wide spectrum of pharmaceutical products catering to diverse therapeutic areas. With a strong presence in India, the United States, and numerous international markets, Zydus Lifesciences is dedicated to addressing unmet medical needs and improving patient outcomes worldwide. Their infrastructure supports end-to-end pharmaceutical solutions, from drug discovery to commercialization, ensuring quality and accessibility across its product range. They are constantly striving to improve health outcomes and the quality of life across the globe. The organization operates through distinct divisions focused on Pharmaceuticals, which are its central activity. They make active pharmaceutical ingredients, finished formulas for doses, generics, biosimilars, novel products, and specialty products. It also has a division dedicated to Consumer Products. This dual focus allows Zydus Lifesciences to leverage its scientific expertise to create both prescription medications and over-the-counter healthcare solutions. The company's dedication to research and development is evident in its consistent introduction of innovative products and therapies. Zydus Lifesciences distinguishes itself through its dedication to quality, safety, and affordability, making it a trusted partner in healthcare. Zydus Lifesciences extends its reach beyond prescription medications through a well-established portfolio of well-known consumer brands. These include brands in personal care, food and nutrition, and everyday health. These product lines, which include personal care products, nutritional supplements, and wellness goods, reflect the company's comprehensive approach to health and well-being. They are dedicated to providing accessible and high-quality options to consumers. Through this multi-pronged strategy, Zydus Lifesciences continues to expand its footprint in the healthcare industry, further solidifying its position as a leading and responsible global healthcare provider.

Company Details

Symbol:ZYDUSLIFE
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:https://zyduslife.com

Key Leadership

Dr. Sharvil Pankajbhai Patel
MD & Executive Director
Mr. Punit Patel
President & CEO of America
Mr. Tushar Dhansukh Shroff
President of Finance & CFO

Corporate Events

Upcoming
Earnings Date
2026-02-04
Recent
Ex-Dividend Date
2025-07-25

Latest News

Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market - Yahoo! Finance Canada
Yahoo! Finance Canada• 11/26/2025
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada - Yahoo! Finance Canada
Yahoo! Finance Canada• 12/9/2025
Indian pharma stocks fall as Trump moves to cut U.S. drug prices - Reuters
Reuters• 5/11/2025

ZYDUSLIFE Share Price: Frequently Asked Questions

What is the current share price of Zydus Lifesciences Ltd (ZYDUSLIFE)?

As of 30 Mar 2026, 12:03 pm IST, Zydus Lifesciences Ltd share price is ₹871.20. The ZYDUSLIFE stock has a market capitalisation of ₹94.25K (Cr) on NSE/BSE.

Is ZYDUSLIFE share price Overvalued or Undervalued?

ZYDUSLIFE share price is currently trading at a P/E ratio of 18.74x, compared to the industry average of 31.77x. Based on this relative valuation, the Zydus Lifesciences Ltd stock appears to be Undervalued against its sector peers.

What is the 52-week high and low of ZYDUSLIFE share price?

The 52-week high of ZYDUSLIFE share price is ₹1059.05 and the 52-week low is ₹795.00. These values are updated daily from NSE/BSE price data.

What factors affect the Zydus Lifesciences Ltd share price?

Key factors influencing ZYDUSLIFE share price include quarterly earnings growth (Sales Growth: 16.92%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Zydus Lifesciences Ltd a good stock for long-term investment?

Zydus Lifesciences Ltd shows a 5-year Profit Growth of 25.92% and an ROE of 21.21%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.38 before investing in ZYDUSLIFE shares.

How does Zydus Lifesciences Ltd compare with its industry peers?

Zydus Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare ZYDUSLIFE share price P/E of 18.74x and ROE of 21.21% against the industry averages to determine competitive standing.

What is the P/E ratio of ZYDUSLIFE and what does it mean?

ZYDUSLIFE share price has a P/E ratio of 18.74x compared to the industry average of 31.77x. Investors pay ₹19 for every ₹1 of annual earnings.

How is ZYDUSLIFE performing according to Bull Run's analysis?

ZYDUSLIFE has a Bull Run fundamental score of 68.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does ZYDUSLIFE belong to?

ZYDUSLIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zydus Lifesciences Ltd share price.

What is Return on Equity (ROE) and why is it important for ZYDUSLIFE?

ZYDUSLIFE has an ROE of 21.21%, which indicates excellent management efficiency. ROE measures how efficiently Zydus Lifesciences Ltd generates profits from shareholders capital.

How is ZYDUSLIFE debt-to-equity ratio and what does it indicate?

ZYDUSLIFE has a debt-to-equity ratio of 0.38, which indicates moderate leverage that should be monitored.

What is ZYDUSLIFE dividend yield and is it a good dividend stock?

ZYDUSLIFE offers a dividend yield of 1.17%, meaning you receive ₹1.17 annual dividend for every ₹100 invested in Zydus Lifesciences Ltd shares.

How has ZYDUSLIFE share price grown over the past 5 years?

ZYDUSLIFE has achieved 5-year growth rates of: Sales Growth 10.27%, Profit Growth 25.92%, and EPS Growth 26.36%.

What is the promoter holding in ZYDUSLIFE and why does it matter?

Promoters hold 74.99% of ZYDUSLIFE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Zydus Lifesciences Ltd.

What is ZYDUSLIFE market capitalisation category?

ZYDUSLIFE has a market capitalisation of ₹94254 crores, placing it in the Large-cap category.

How volatile is ZYDUSLIFE stock?

ZYDUSLIFE has a beta of N/A. A beta > 1 suggests the Zydus Lifesciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is ZYDUSLIFE operating profit margin trend?

ZYDUSLIFE has a 5-year average Operating Profit Margin (OPM) of 25.73%, indicating the company's operational efficiency.

How is ZYDUSLIFE quarterly performance?

Recent quarterly performance shows Zydus Lifesciences Ltd YoY Sales Growth of 16.92% and YoY Profit Growth of 40.92%.

What is the institutional holding pattern in ZYDUSLIFE?

ZYDUSLIFE has FII holding of 7.34% and DII holding of 10.86%. Significant institutional holding often suggests professional confidence in the Zydus Lifesciences Ltd stock.

HomeScreenerBattleWatchlist

Frequently Asked Questions about Zydus Lifesciences Ltd

What is the current share price of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd (ZYDUSLIFE) trades at ₹871.20 on NSE and BSE. Market cap ₹94.25K (Cr). Educational data only.

What is the P/E ratio of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd has a P/E of 18.74x vs industry average 31.77x.

What is the Bull Run score for Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd has a Bull Run score of 68.7/100 based on 25+ financial parameters.

Does Zydus Lifesciences Ltd pay dividends?

Zydus Lifesciences Ltd has a dividend yield of 1.17%. Past dividends don't guarantee future payments.

What is the ROE of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd has ROE of 21.21%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd has debt-to-equity of 0.38.

Is Zydus Lifesciences Ltd a good investment?

Bull Run gives Zydus Lifesciences Ltd a score of 68.7/100. This is not investment advice — consult a SEBI-registered advisor.